Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

[Targeting--a new way to identify unknown tumor markers in blood vessels].

Wallin E, Akerman ME, Palmblad J.

Lakartidningen. 2005 Feb 21-27;102(8):551-2, 554-5. Review. Swedish.

PMID:
15786906
2.

Angiostatic peptides use plasma fibronectin to home to angiogenic vasculature.

Akerman ME, Pilch J, Peters D, Ruoslahti E.

Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):2040-5. Epub 2005 Feb 1.

3.

Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells.

Laakkonen P, Akerman ME, Biliran H, Yang M, Ferrer F, Karpanen T, Hoffman RM, Ruoslahti E.

Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9381-6. Epub 2004 Jun 14.

4.

Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels.

Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P, Ruoslahti E.

J Cell Biol. 2003 Nov 24;163(4):871-8.

5.

Anastellin, an FN3 fragment with fibronectin polymerization activity, resembles amyloid fibril precursors.

Briknarov√° K, Akerman ME, Hoyt DW, Ruoslahti E, Ely KR.

J Mol Biol. 2003 Sep 5;332(1):205-15.

PMID:
12946358
6.

Nanocrystal targeting in vivo.

Akerman ME, Chan WC, Laakkonen P, Bhatia SN, Ruoslahti E.

Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12617-21. Epub 2002 Sep 16.

Supplemental Content

Loading ...
Support Center